Literature DB >> 21113600

XPA-210: a new proliferation marker to characterize tumor biology and progression of renal cell carcinoma.

Georgios Gakis1, Joerg Hennenlotter, Marcus Scharpf, Joachim Hevler, David Schilling, Ursula Kuehs, Arnulf Stenzl, Christian Schwentner.   

Abstract

PURPOSE: Recent lung cancer data have shown an association of XPA-210, a key peptide of thymidine kinase, with advanced disease. We thus assessed its proliferation status in primary (M0) and metastatic (M1) renal cell carcinoma (RCC).
METHODS: Paraffin slides from 30 patients (mean age: 61.2 years; range: 42-84) with clear-cell RCC (M0 in 10; non-osseous M1 in 10; osseous M1 in 10) were T-matched for pT1/pT3. Corresponding malignant and benign renal parenchyma were immunohistochemically stained against XPA-210. Staining density was determined by a semi-quantitative score of positive cell shares. Staining intensity included the precise cellular location.
RESULTS: XPA-210 occurred predominantly in the nucleus, with a minor cytoplasmatic component. RCC tissue showed higher density and stronger intensity than did benign renal tissue in both nucleus (P = 0.005) and cytoplasm (P = 0.01). Density and intensity were positively associated with tumor diameters ≤7 cm, whereas they tended to correlate inversely in tumors >7 cm (P 0.07). Density of stained cells was significantly higher in metastatic than in localized RCC in both nucleus and cytoplasm (P < 0.04). Non-osseous M1 tissue showed significantly higher nuclear and cytoplasmatic expression than did M0 tissue (P < 0.05), whereas osseous M1 tissue did not.
CONCLUSIONS: In all RCC tissues, XPA-210 staining was significantly higher in the nucleus than in cytoplasm, potentially owing to large cytoplasmatic spaces as a characteristic histologic feature of clear-cell component. XPA-210 expression gradually increased from localized to metastatic disease, peaking in patients without bone involvement. Therefore, XPA-210 might aid the selection of appropriate adjuvant treatment in high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21113600     DOI: 10.1007/s00345-010-0621-8

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  23 in total

Review 1.  Structure and function of cellular deoxyribonucleoside kinases.

Authors:  S Eriksson; B Munch-Petersen; K Johansson; H Eklund
Journal:  Cell Mol Life Sci       Date:  2002-08       Impact factor: 9.261

2.  Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings.

Authors:  Yan Chen; Mingang Ying; YanSong Chen; Minhua Hu; Yingying Lin; Dedong Chen; Xiaoli Li; Ming Zhang; Xia Yun; Ji Zhou; Ellen He; Sven Skog
Journal:  Int J Clin Oncol       Date:  2010-04-01       Impact factor: 3.402

3.  p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.

Authors:  D Theodorescu; S R Broder; J C Boyd; S E Mills; H F Frierson
Journal:  J Urol       Date:  1997-07       Impact factor: 7.450

4.  Assignment of the gene for galactokinase to human chromosome 17 and its regional localisation to band q21-22.

Authors:  S M Elsevier; R S Kucherlapati; E A Nichols; R P Creagan; R E Giles; F H Ruddle; K Willecke; J K McDougall
Journal:  Nature       Date:  1974-10-18       Impact factor: 49.962

5.  Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients.

Authors:  Zhu-Lin Pan; Xing-Ying Ji; Yan-Min Shi; Ji Zhou; Ellen He; Sven Skog
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-07       Impact factor: 4.553

6.  Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients.

Authors:  P Broët; S Romain; A Daver; G Ricolleau; V Quillien; A Rallet; B Asselain; P M Martin; F Spyratos
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

7.  Specific recognition of cytosolic thymidine kinase in the human lung tumor by monoclonal antibodies raised against recombinant human thymidine kinase.

Authors:  N Kuroiwa; M Nakayama; T Fukuda; H Fukui; H Ohwada; T Hiwasa; S Fujimura
Journal:  J Immunol Methods       Date:  2001-07-01       Impact factor: 2.303

8.  Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.

Authors:  Pengcheng Luo; Ellen He; Staffan Eriksson; Ji Zhou; Guozhu Hu; Jie Zhang; Sven Skog
Journal:  Eur J Cancer Prev       Date:  2009-06       Impact factor: 2.497

9.  Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas.

Authors:  Qimin He; Yongrong Mao; Jainping Wu; Catrine Decker; Malik Merza; Naining Wang; Staffan Eriksson; Juan Castro; Sven Skog
Journal:  Int J Oncol       Date:  2004-10       Impact factor: 5.650

10.  The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer.

Authors:  L Zou; P G Zhang; S Zou; Y Li; Q He
Journal:  Int J Biol Markers       Date:  2002 Apr-Jun       Impact factor: 3.248

View more
  6 in total

1.  High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma.

Authors:  Yan Xu; Qun-Li Shi; Henghui Ma; Hangbo Zhou; Zhenfeng Lu; Bo Yu; Xiaojun Zhou; Staffan Eriksson; Ellen He; Sven Skog
Journal:  Tumour Biol       Date:  2011-12-06

2.  XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence.

Authors:  Stefan Aufderklamm; Jörg Hennenlotter; Tilman Todenhoefer; Georgios Gakis; David Schilling; Ulrich Vogel; Ursula Kuehs; Johannes Dlugosch; Judith Knapp; Axel Merseburger; Valentina Gerber; Anna Ordelheide; Joachim Hevler; Arnulf Stenzl; Christian Schwentner
Journal:  World J Urol       Date:  2011-10-04       Impact factor: 4.226

3.  Thymidine kinase 1 silencing retards proliferative activity of pancreatic cancer cell via E2F1-TK1-P21 axis.

Authors:  Xiaole Zhu; Chenyuan Shi; Yunpeng Peng; Lingdi Yin; Min Tu; Qiuyang Chen; Chaoqun Hou; Qiang Li; Yi Miao
Journal:  Cell Prolif       Date:  2017-12-20       Impact factor: 6.831

Review 4.  The proliferation marker thymidine kinase 1 in clinical use.

Authors:  Ji Zhou; Ellen He; Sven Skog
Journal:  Mol Clin Oncol       Date:  2012-09-04

5.  STK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data.

Authors:  Zhenxin Wang; Guoqing Zhang; Zhongcheng Li; Jin Li; Hongbo Ma; Ailian Hei; Shunchang Jiao; Yi Hu; Shengjie Sun; Liangliang Wu; Ji Zhou; Yu Wang; Ellen He; Sven Skog
Journal:  Future Sci OA       Date:  2020-11-23

6.  Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix.

Authors:  Gang Chen; Cheng He; Ling Li; An Lin; Xiongwei Zheng; Ellen He; Sven Skog
Journal:  BMC Cancer       Date:  2013-05-21       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.